Armo Biosciences nabs $67 mln
Redwood City, California-based Armo BioSciences Inc, a late-stage immuno-oncology company, has closed $67 million in financing. Qiming Venture Partners led the round with participation from Decheng Capital, Sequoia Capital, Quan Capital, RTW Investments, Kleiner Perkins Caufield and Byers, OrbiMed, DAG Ventures, NanoDimension, HBM Healthcare Investments, GV, Celgene Corporation and funds advised by Clough Capital Partners L.P. In conjunction with the financing, Dr. Stella Xu of Quan Capital and Dr. Min Cui of Decheng Capital have joined Armo's board of directors.
31 August 2017•1 min read
